Language: BG BG
← Back to results
Recruiting Phase 3 NCT05878769

A Study to Evaluate the Long-Term Safety of Astegolimab in Participants With Chronic Obstructive Pulmonary Disease (COPD)

Phase 3 – large-scale trial before approval
Conditions: Chronic Obstructive Pulmonary Disease

Sponsor: Hoffmann-La Roche

trial.available_in: БГ
Overview
The purpose of this study is to assess the long-term safety and to explore the efficacy of astegolimab in participants with chronic obstructive pulmonary disease (COPD) who have completed the 52-week placebo-controlled treatment period in parent studies GB43311 or GB44332.
Who can participate
Inclusion Criteria: * Completion of the 52-week treatment period in either parent GB43311 or GB44332 Exclusion Criteria: * Withdrawal of consent and/or premature discontinuation from parent study * Any permanent discontinuation of study drug in parent study * Significant non-compliance in the parent study, specifically defined as missing scheduled visits, per investigator's judgment * Any new diagnosis of asthma according to the Global Initiative for Asthma guidelines or other accepted guidelines since enrolling in the parent study * Any new clinically significant pulmonary disease other than COPD (e.g., pulmonary fibrosis, sarcoidosis, chronic pulmonary embolism or primary pulmonary hypertension, alpha-1-antitrypsin deficiency) since enrolling in the parent study * Any new unstable cardiac disease, myocardial infarction, or New York Heart Association Class III or IV heart failure since enrolling in the parent study
Locations 37
Argentina (1)
Centro Medico Capital
La Plata , Buenos Aires
Australia (1)
Flinders Medical Centre
Bedford Park , South Australia
Belgium (1)
AZ Sint-Jan Brugge-Oostende
Bruges
Brazil (1)
LMK Servicos Medicos SS
Porto Alegre , Rio Grande do Sul
Bulgaria (1)
MHAT Knyaginya Klementina Sofia EAD
Sofia , Sofia-Grad
Canada (1)
Edmonton Respiratory Consultants
Edmonton , Alberta
Chile (1)
Centro de Estudios Clinicos
Ñuñoa
China (1)
Anhui Chest Hospital
Hefei , Anhui
Czech Republic (1)
Plicní ambulance MUDr. I. Cierná Peterová s.r.o.
Brandýs nad Labem-Stará Boleslav
Denmark (1)
Aalborg Universitetshospital
Aalborg
France (1)
Clinique de l'Europe
Amiens
Greece (1)
Evangelismos General Hospital of Athens
Athens
Hong Kong (1)
Tuen Mun Hospital
Hong Kong
Hungary (1)
Obudai Egeszsegugyi Centrum Kft.-Budapest
Budapest
India (1)
Paarthiv Lung Care Center
Hyderabad , Andhra Pradesh
Israel (1)
Assuta Ashdod Medical Center
Ashdod
Italy (1)
Azienda Ospedaliera Dei Colli
Naples , Campania
Japan (1)
Japan Community Health Care Organization Hokkaido Hospital
Toyohira-ku, Sapporo City , Hokkaido
Kenya (1)
KEMRI-MTWAPA Clinical Trial Site
Kilifi
Latvia (1)
Daugavpils Regional Hospital
Daugavpils
Mexico (1)
CICUM San Miguel
Guadalajara , Jalisco
ACTIVE_NOT_RECRUITING
Netherlands (1)
Meander Medisch Centrum
Amersfoort
New Zealand (1)
P3 Research - Kapiti - PPDS
Waikanae , Wellington Region
Peru (1)
Clinica Providencia (Inverconsult Sociedad Anonima) - PPDS
San Miguel , Lima region
Philippines (1)
Manila Central University-Filemon D Tanchoco Medical Foundation
Caloocan
Poland (1)
Viltis Medica Sp. Z o.o.
Trzebnica , Lower Silesian Voivodeship
Puerto Rico (1)
Allianze Pulmonary Research LLC
Guaynabo
Romania (1)
Neomed Out-Patient Treatment and Diagnosis Medical Center SRL
Brasov
South Africa (1)
Johese Clinical Research
City of Tshwane , Gauteng
South Korea (1)
Soon Chun Hyang University Hospital Bucheon
Bucheon-si
Spain (1)
Hospital de Merida
Mérida , Badajoz
Sweden (1)
Fysikalisk Medicin i Stockholm AB
Lidingö
Taiwan (1)
Changhua Christian Hospital
Chang-hua
Thailand (1)
Srinagarind Hospital, Khon Kaen University
Khon Kaen
Turkey (1)
Cukurova University Medical Faculty Balcali Hospital
Adana
United Kingdom (1)
Guys Hospital
London , Middlesex
United States (1)
UAB Lung Health Center
Birmingham , Alabama
Technical details
Status
Recruiting
Phase
Phase 3
Study type
INTERVENTIONAL
Sex
Male and female
Minimum age
40 Years
Maximum age
90 Years
Healthy volunteers
No
Start date
28.06.2023
Completion date
30.06.2027
Registry ID
NCT05878769
Source
anzctr
trial.inquiry_btn

Information is automatically extracted from ClinicalTrials.gov. Consult your doctor before taking action.